Tesla's non-Gaap medications prohibit non-money things as stock based remuneration, this incorporates the adjustment in reasonable esteem identified with teslas warrant risk, and non-money cost identified with teslas 1.5% convertible senior notes, and one-time costs related with the early reimbursement of the 2010 advance Tesla got from the division of vitality.